Seegene, a company specializing in molecular diagnostics, said it won a 62.7 billion won ($46.1 million) contract to supply its diagnostic reagents to Italy.
Seegene said Italy Arrow Diagnostics S.r.l. had been selected as a supplier in the diagnostic reagent bidding, which the Tuscany government hosts every five years.
Demands of diagnosic reagent in Italy rised as medical facilities noticed the usability of molecular diagnotics during the pandemic, the company said.
Under the contract, Seegene will supply various types of diagnostic kits, including those testing HPV, STI, Entero DR, MTB, and Covid-19, to 13 public hospitals in Tuscany from January 2023.
Among the test kits to be supplied, 57 percent will be Covid-19 test kits, and 43 percent, non-Covid-19 test devices, Seegene said.
“We expect that the success in the bidding would bring positive results in tenders in other regions of Italy and increase sales of non-Covid products steadily,” said Maccheroni Franco, a CEO of Arrow Diagnostics S.r.l.